Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that ...

Triple therapy inhalers are expected to account for 11.3% of the total market. The chronic obstructive pulmonary disease ...

Background and Goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma ...

Long-distance caregivers can help manage a loved one’s finances, organize their medical appointments, coordinate with other ...

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, ...

Novartis and Qualcomm are to develop a 'smart' COPD inhaler to allow patients to digitally monitor their medication. The announcement follows similar plans by Novartis's rivals in the respiratory ...

smart inhalers market report highlights transformative digital innovations in respiratory care, improved patient adherence, and forecasted growth through 2035 ...

Background and goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma ...

Adults with COPD who used inhaled corticosteroids for more than ... need to weigh the risks and benefits before initiating treatment,” Yawn told Healio. “This information should help with ...

With Medicare coverage, a person can still have certain out-of-pocket costs for an inhaler. Out-of-pocket cost: This is the amount a person must pay for care when Medicare does not pay the total ...

Significantly greater composite adverse outcome rates seen for long- vs short-term inhaled corticosteroid use for prevalent, inception cohorts. HealthDay News — For patients with chronic ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...